Ionis Pharmaceuticals (IONS) News Today $42.72 +0.55 (+1.29%) Closing price 03:59 PM EasternExtended Trading$42.50 -0.22 (-0.51%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Ionis Pharmaceuticals (NASDAQ:IONS) Given New $49.00 Price Target at JPMorgan Chase & Co.August 27 at 10:35 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Earns "Buy" Rating from Needham & Company LLCAugust 27 at 8:26 AM | marketbeat.comAllene Diaz Sells 1,427 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) StockAugust 27 at 7:20 AM | insidertrades.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) StockAugust 27 at 2:31 AM | americanbankingnews.comIonis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued PharmaAugust 26 at 4:09 PM | seekingalpha.comWilliam Blair Has Negative Outlook of IONS FY2029 EarningsAugust 26 at 2:16 AM | marketbeat.comIonis Pharmaceuticals price target raised to $49 from $48 at JPMorganAugust 25 at 9:51 PM | msn.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $58.00August 25 at 2:59 AM | americanbankingnews.comWells Fargo & Company Raises Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $82.00August 25 at 2:59 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $65.00 at Piper SandlerAugust 24 at 9:34 AM | marketbeat.comBarclays Raises Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $58.00August 24 at 9:10 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Given New $82.00 Price Target at Wells Fargo & CompanyAugust 24 at 8:44 AM | marketbeat.comHC Wainwright Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock PriceAugust 24 at 8:19 AM | marketbeat.comCitigroup Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) StockAugust 24 at 4:15 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Given New $70.00 Price Target at HC WainwrightAugust 24 at 2:17 AM | americanbankingnews.comIonis Pharmaceuticals price target raised to $64 from $63 at BofAAugust 23, 2025 | msn.comCandriam S.C.A. Boosts Stock Position in Ionis Pharmaceuticals, Inc. $IONSAugust 23, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 23, 2025 | marketbeat.comIonis Pharmaceuticals price target raised to $69 from $65 at CitiAugust 22, 2025 | msn.comIonis Pharmaceuticals price target raised to $70 from $65 at H.C. WainwrightAugust 22, 2025 | msn.comIonis Pharmaceuticals price target raised to $58 from $57 at BarclaysAugust 22, 2025 | msn.comIonis Pharmaceuticals price target raised to $82 from $77 at Wells FargoAugust 22, 2025 | msn.comBeyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals StockAugust 22, 2025 | benzinga.comIonis Pharmaceuticals, Inc. $IONS Shares Acquired by T. Rowe Price Investment Management Inc.August 22, 2025 | marketbeat.comUS FDA approves Ionis' drug for rare genetic disorderAugust 21, 2025 | reuters.comDAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedemaAugust 21, 2025 | businesswire.comC Frank Bennett Sells 10,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) StockAugust 21, 2025 | insidertrades.comGroupama Asset Managment Has $32.26 Million Position in Ionis Pharmaceuticals, Inc. $IONSAugust 21, 2025 | marketbeat.comAberdeen Group plc Buys 44,696 Shares of Ionis Pharmaceuticals, Inc. $IONSAugust 21, 2025 | marketbeat.comTocqueville Asset Management L.P. Sells 164,745 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)August 19, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 37,811 Shares of Ionis Pharmaceuticals, Inc. $IONSAugust 19, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Liontrust Investment Partners LLPAugust 18, 2025 | marketbeat.comSector Gamma AS Boosts Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)August 17, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded at Wall Street ZenAugust 17, 2025 | marketbeat.comVanguard Group Inc. Has $494.30 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)August 16, 2025 | marketbeat.comUBS Sticks to Their Hold Rating for Ionis Pharmaceuticals (IONS)August 14, 2025 | theglobeandmail.comUBS Group Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) StockAugust 13, 2025 | marketbeat.comIonis Pharmaceuticals price target raised to $46 from $45 at UBSAugust 12, 2025 | msn.comXTX Topco Ltd Sells 12,958 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)August 11, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director B Lynne Parshall Sells 5,000 SharesAugust 10, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of IONS Q3 EarningsAugust 9, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Sells $209,650.00 in StockAugust 9, 2025 | insidertrades.comCommerce Bank Reduces Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)August 9, 2025 | marketbeat.comRichard S. Geary Sells 10,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockAugust 7, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard S. Geary Sells 10,000 SharesAugust 7, 2025 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc.August 7, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $408,697.20 in StockAugust 6, 2025 | marketbeat.comEugene Schneider Sells 9,549 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockAugust 6, 2025 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Raiffeisen Bank International AGAugust 6, 2025 | marketbeat.comIQ EQ FUND MANAGEMENT IRELAND Ltd Acquires Shares of 8,059 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)August 6, 2025 | marketbeat.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.740.97▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼428▲IONS Articles Average Week Get the Latest News and Ratings for IONS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ionis Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BIIB News Today INCY News Today UTHR News Today NBIX News Today BMRN News Today EXEL News Today MDGL News Today EXAS News Today HALO News Today RGEN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access